BSE filing, NSE: NATRAJPR. Summary written from the filing by ALFA Finder's alert engine.
Natraj Proteins Ltd: key numbers
- Share price
- ₹35.80
- Market cap
- ₹13.41 Cr
- Revenue (annual)
- ₹101.1 Cr
- Net profit (annual)
- ₹1.14 Cr
- P/E (TTM)
- 3.0×Sector 38.6×
- Promoter holding
- 41.79%-0.03% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Natraj Proteins Ltd
All →Natraj Proteins Board Meeting Date
Natraj Proteins intimated a board meeting on 29 October 2026 to consider unaudited results for the quarter and half-year ended 30 September 2026. Trading window remains closed until 48 hours after results are declared.
Natraj Proteins Other Announcement
Natraj Proteins Ltd submitted its quarterly shareholding pattern for the quarter ended September 30, 2026, as per regulatory requirements.
Natraj Proteins Management Change
Natraj Proteins Limited re-appointed Mr. Sharad Kumar Jain as Executive Director for a 36-month term effective October 1, 2026.
- Execution
- 36 months
Natraj Proteins Annual General Meeting
Natraj Proteins Limited submitted proceedings of its 35th Annual General Meeting held on September 29, 2026. Key resolutions included adopting financial statements and re-appointing directors.
Natraj Proteins Annual Report
Natraj Proteins filed its 35th Annual Report for FY 2025-26 with the AGM notice. The report recaps existing crushing and refining capacity under Regulation 34(1).
Natraj Proteins Annual General Meeting
Natraj Proteins Limited announced its 35th Annual General Meeting will be held on September 29, 2026. Share transfer books will be closed from September 23 to 29, 2026.
Other other announcement announcements
All →Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.
Avience Biomedicals Other Announcement
Avience Biomedicals confirmed corporate governance compliance is not applicable, as it is SME-listed on NSE Emerge. No quarterly governance report is required for September 2026.